New treatments for colorectal cancer using BET degraders
BET degraders for improving colorectal cancer therapy
This study is exploring new treatments for colorectal cancer by using special drugs that target certain proteins to help kill cancer cells better, especially for patients whose current treatments aren't working well.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Southern California NIH-funded |
| Lab location | 1 site (Los Angeles, UNITED STATES) |
| Project ID | NIH-11074634 on NIH RePORTER |
What this research studies
This research focuses on developing innovative therapies for colorectal cancer (CRC) by targeting specific proteins that contribute to cancer progression. The approach involves using small-molecule inhibitors that degrade BET proteins, which have shown promise in preliminary studies for their ability to enhance cancer cell death. By understanding how these agents work, the research aims to improve treatment outcomes for patients with advanced CRC who have not responded well to existing therapies. The study will involve laboratory experiments and patient-derived models to evaluate the effectiveness of these new agents.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with advanced or metastatic colorectal cancer who have not responded to standard therapies.
Not a fit: Patients with early-stage colorectal cancer or those who have not yet undergone treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with colorectal cancer, potentially improving survival rates and quality of life.
How similar studies have performed: Other research has shown promising results with similar approaches targeting BET proteins, indicating potential for success in this area.
Where this research is happening
Los Angeles, UNITED STATES
- University of Southern California — Los Angeles, United States (Active)
Researchers
- Principal investigator: Zhang, Lin — University of Southern California
- Study coordinator: Zhang, Lin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.